Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

New medication for hepatocellular carcinoma: atezolizumab + bevacizumab

Thursday 30 May 2024

We have added a new primary medication to the hepatocellular carcinoma (HCC) indication, atezolizumab + bevacizumab. These two monoclonal antibodies are indicated in combination for the treatment of advanced or unresectable HCC in adults who have not received prior systemic therapy.

This brings the number of our HCC drugs to five and the total number of hepatology drugs on our interaction checker to twenty-seven.

We have uploaded PK factsheets to the Prescribing Resources section for atezolizumab and bevacizumab separately. The Interactions with HCC treatment table is yet to be updated, due to the on-going issues with the View All function on the website.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016